HEALTH
Novel JAK1 Inhibitor Reduced Treatment Failures in Active Noninfectious Uveitis
![Novel JAK1 Inhibitor Reduced Treatment Failures in Active Noninfectious Uveitis](https://connecticutnewspress.com/wp-content/uploads/2024/07/15155-novel-jak1-inhibitor-reduced-treatment-failures-in-active-noninfectious-uveitis-780x470.jpg)
MedPage Today) — An investigational Janus kinase 1 (JAK1) preferential inhibitor reduced the risk of treatment failure among patients with active noninfectious uveitis, the phase II randomized HUMBOLDT trial showed.
Though the trial was stopped…